FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2175470508> ?p ?o ?g. }

• W2175470508 endingPage "46" @default.
• W2175470508 startingPage "35" @default.
• W2175470508 abstract "Background Relapses of multiple sclerosis decrease during pregnancy, when the hormone estriol is increased. Estriol treatment is anti-inflammatory and neuroprotective in preclinical studies. In a small single-arm study of people with multiple sclerosis estriol reduced gadolinium-enhancing lesions and was favourably immunomodulatory. We assessed whether estriol treatment reduces multiple sclerosis relapses in women. Methods We did a randomised, double-blind, placebo-controlled phase 2 trial at 16 academic neurology centres in the USA, between June 28, 2007, and Jan 9, 2014. Women aged 18–50 years with relapsing-remitting multiple sclerosis were randomly assigned (1:1) with a random permuted block design to either daily oral estriol (8 mg) or placebo, each in combination with injectable glatiramer acetate 20 mg daily. Patients and all study personnel, except for pharmacists and statisticians, were masked to treatment assignment. The primary endpoint was annualised relapse rate after 24 months, with a significance level of p=0·10. Relapses were confirmed by an increase in Expanded Disability Status Scale score assessed by an independent physician. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00451204. Findings We enrolled 164 patients: 83 were allocated to the estriol group and 81 were allocated to the placebo group. The annualised confirmed relapse rate was 0·25 relapses per year (95% CI 0·17–0·37) in the estriol group versus 0·37 relapses per year (0·25–0·53) in the placebo group (adjusted rate ratio 0·63, 95% CI 0·37–1·05; p=0·077). The proportion of patients with serious adverse events did not differ substantially between the estriol group and the placebo group (eight [10%] of 82 patients vs ten [13%] of 76 patients). Irregular menses were more common in the estriol group than in the placebo group (19 [23%] vs three [4%], p=0·0005), but vaginal infections were less common (one [1%] vs eight [11%], p=0·0117). There were no differences in breast fibrocystic disease, uterine fibroids, or endometrial lining thickness as assessed by clinical examination, mammogram, uterine ultrasound, or endometrial lining biopsy. Interpretation Estriol plus glatiramer acetate met our criteria for reducing relapse rates, and treatment was well tolerated over 24 months. These results warrant further investigation in a phase 3 trial. Funding National Institutes of Health, National Multiple Sclerosis Society, Conrad N Hilton Foundation, Jack H Skirball Foundation, Sherak Family Foundation, and the California Community Foundation." @default.
• W2175470508 created "2016-06-24" @default.
• W2175470508 creator A5002607431 @default.
• W2175470508 creator A5007084737 @default.
• W2175470508 creator A5008002660 @default.
• W2175470508 creator A5008598861 @default.
• W2175470508 creator A5010540807 @default.
• W2175470508 creator A5014370231 @default.
• W2175470508 creator A5015377812 @default.
• W2175470508 creator A5019139141 @default.
• W2175470508 creator A5020742042 @default.
• W2175470508 creator A5021514185 @default.
• W2175470508 creator A5028071943 @default.
• W2175470508 creator A5029589010 @default.
• W2175470508 creator A5035522236 @default.
• W2175470508 creator A5038587842 @default.
• W2175470508 creator A5043088536 @default.
• W2175470508 creator A5045759295 @default.
• W2175470508 creator A5049324725 @default.
• W2175470508 creator A5058205908 @default.
• W2175470508 creator A5058615969 @default.
• W2175470508 creator A5061039500 @default.
• W2175470508 creator A5067116063 @default.
• W2175470508 creator A5067160651 @default.
• W2175470508 creator A5072000852 @default.
• W2175470508 creator A5076423610 @default.
• W2175470508 creator A5076747036 @default.
• W2175470508 creator A5085348888 @default.
• W2175470508 creator A5085986981 @default.
• W2175470508 date "2016-01-01" @default.
• W2175470508 modified "2023-10-17" @default.
• W2175470508 title "Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial" @default.
• W2175470508 cites W1543098232 @default.
• W2175470508 cites W1593442063 @default.
• W2175470508 cites W1959858628 @default.
• W2175470508 cites W1969965083 @default.
• W2175470508 cites W1973283233 @default.
• W2175470508 cites W1983895762 @default.
• W2175470508 cites W1987957521 @default.
• W2175470508 cites W1988037885 @default.
• W2175470508 cites W1994551577 @default.
• W2175470508 cites W1998609863 @default.
• W2175470508 cites W1999158626 @default.
• W2175470508 cites W1999269923 @default.
• W2175470508 cites W1999493557 @default.
• W2175470508 cites W2001510535 @default.
• W2175470508 cites W2008758766 @default.
• W2175470508 cites W2012934594 @default.
• W2175470508 cites W2014696622 @default.
• W2175470508 cites W2024695613 @default.
• W2175470508 cites W2034456343 @default.
• W2175470508 cites W2041678822 @default.
• W2175470508 cites W2043533523 @default.
• W2175470508 cites W2045940737 @default.
• W2175470508 cites W2047482975 @default.
• W2175470508 cites W2062283207 @default.
• W2175470508 cites W2065085361 @default.
• W2175470508 cites W2079723480 @default.
• W2175470508 cites W2087527641 @default.
• W2175470508 cites W2088993196 @default.
• W2175470508 cites W2091757374 @default.
• W2175470508 cites W2104233628 @default.
• W2175470508 cites W2106115061 @default.
• W2175470508 cites W2113912597 @default.
• W2175470508 cites W2122094983 @default.
• W2175470508 cites W2122545833 @default.
• W2175470508 cites W2135551891 @default.
• W2175470508 cites W2139367012 @default.
• W2175470508 cites W2149721689 @default.
• W2175470508 cites W2169730727 @default.
• W2175470508 cites W2319459971 @default.
• W2175470508 cites W3141386680 @default.
• W2175470508 cites W4366064463 @default.
• W2175470508 cites W4376043785 @default.
• W2175470508 cites W4379196482 @default.
• W2175470508 doi "https://doi.org/10.1016/s1474-4422(15)00322-1" @default.
• W2175470508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26621682" @default.
• W2175470508 hasPublicationYear "2016" @default.
• W2175470508 type Work @default.
• W2175470508 sameAs 2175470508 @default.
• W2175470508 citedByCount "145" @default.
• W2175470508 countsByYear W21754705082016 @default.
• W2175470508 countsByYear W21754705082017 @default.
• W2175470508 countsByYear W21754705082018 @default.
• W2175470508 countsByYear W21754705082019 @default.
• W2175470508 countsByYear W21754705082020 @default.
• W2175470508 countsByYear W21754705082021 @default.
• W2175470508 countsByYear W21754705082022 @default.
• W2175470508 countsByYear W21754705082023 @default.
• W2175470508 crossrefType "journal-article" @default.
• W2175470508 hasAuthorship W2175470508A5002607431 @default.
• W2175470508 hasAuthorship W2175470508A5007084737 @default.
• W2175470508 hasAuthorship W2175470508A5008002660 @default.
• W2175470508 hasAuthorship W2175470508A5008598861 @default.
• W2175470508 hasAuthorship W2175470508A5010540807 @default.
• W2175470508 hasAuthorship W2175470508A5014370231 @default.
• W2175470508 hasAuthorship W2175470508A5015377812 @default.
• W2175470508 hasAuthorship W2175470508A5019139141 @default.

• next